EU fines generic-drug companies to end "pay for delay" deals

06/3/2013 | Chicago Tribune (tiered subscription model)

The European Commission has announced fines against Lundbeck in Denmark, Merck in Germany and seven smaller firms for arrangements under which brand-name drug companies paid generic manufacturers to delay production of cheaper off-patent medicines. The fines mark a continuing effort by EU and US regulators to end such "pay for delay" tactics by large pharmaceutical firms. Lundbeck denied wrongdoing.

View Full Article in:

Chicago Tribune (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ